Recently, SPAC company DT Cloud Acquisition (DYCQ) announced that it has signed a non-binding letter of intent with Shanghai Maius Pharmaceutical Technology Co., LTD. (Shanghai Guiyan Pharmaceutical Technology Co., Ltd., hereinafter referred to as "Guiyan Pharmaceutical") to conduct a business combination. According to the letter of intent, DT Cloud Acquisition will acquire 100% of the issued share capital and share equivalents of Shanghai Guiyan Pharmaceutical Technology Co., Ltd. or all of its businesses. The specific transaction structure will be determined later by both parties based on the results of further due diligence and other considerations. It is expected that more details of the combination will be announced in the fourth quarter of 2024. Founded in 2015, Guiyan Pharmaceutical is a biomedical technology R&D company taking innovative preparations and new-target small-molecule chemical drugs as its core competitiveness. As of the closing on September 10, DT Cloud Acquisition closed at $10.30 per share, with a current market capitalization of approximately $92.318 million. © 2021 Meishun (Hong Kong) Management Consulting Co., Ltd. and Meishun (Hangzhou) Management Consulting Co., Ltd. All rights reserved. Meishun Meiyin (Hangzhou) Consulting Management Co., Ltd. is the domestic subsidiary of Hong Kong Meishun Management Consulting Co., Ltd. under the same actual controller. Both companies share the same actual controller, are under unified China-based management, and comply with the laws of Hong Kong and mainland China.